Expedited Pathways & Biopharma Dealmaking
In 2026, expedited FDA pathways—including Breakthrough Therapy, Fast Track, and Priority Review designations—have emerged as major drivers of biopharma M&A and licensing activity. By accelerating clinical development and regulatory review timelines, these designations help reduce the commercial risks posed by the industry’s approaching “patent cliff,” fueling a wave of high-value strategic partnerships and acquisitions. Key trends shaping the 2026 biopharma dealmaking landscape are given below.
Faster Deal Execution Timelines
The looming wave of blockbuster patent expirations has created a significant revenue gap for major pharmaceutical companies. To counter this pressure, Big Pharma is increasingly pursuing acquisitions of early- and mid-stage assets immediately after they receive Breakthrough Therapy or Fast Track designation. These expedited FDA pathways provide regulatory validation that lowers development risk, enabling companies to justify multi-billion-dollar acquisitions even before Phase III completion.
Examples:
- Merck’s acquisition of Terns Pharmaceuticals: In early 2026, Merck finalised a $6.7 billion acquisition of Terns Pharmaceuticals. The deal focused on pipeline assets benefiting from fast-track regulatory mechanisms, allowing Merck to quickly strengthen its portfolio with de-risked programs ahead of major patent expirations.
- Eli Lilly’s acquisition of Centessa Pharmaceuticals: Eli Lilly completed a $7.8 billion acquisition of Centessa Pharmaceuticals, targeting late-stage, highly validated assets positioned for accelerated regulatory progression. The agreement included a substantial $6.3 billion upfront payment to rapidly secure the opportunity.
Higher Valuations for Phase II Assets
Programs granted expedited designations are commanding significant acquisition and licensing premiums. Deal structures are increasingly combining large upfront payments with milestone-based payouts to balance commercial opportunity against clinical risk. CNS and oncology companies with accelerated-development platforms remain particularly attractive acquisition targets.
Examples:
- Sanofi’s acquisition of Blueprint Medicines: Sanofi agreed to acquire Blueprint Medicines in a $9.5 billion transaction. Due to the expedited status of Blueprint’s oncology and rare disease portfolio, Sanofi committed $9.1 billion upfront, with the remaining $400 million tied to future regulatory milestones.
- Pfizer’s Metsera transaction: Pfizer entered the competitive obesity market through a deal with Metsera valued at up to $10 billion. Given the earlier-stage nature of the platform, the agreement relied heavily on milestone-driven payments linked to clinical and regulatory achievements.
Growing Emphasis on AI-Enabled Platforms
With patent cliffs accelerating the need for rapid innovation, pharmaceutical companies are increasingly prioritizing AI- and machine learning-driven platforms in M&A strategy. Acquirers view AI-native technologies as critical tools for shortening preclinical timelines, improving trial efficiency, and optimising navigation through expedited regulatory pathways.
Examples:
- Thermo Fisher Scientific’s acquisition of Clario: Thermo Fisher completed a $9 billion acquisition of Clario, whose AI-enabled clinical trial and data management technologies supported nearly 70% of FDA drug approvals over the previous decade. Such platforms are increasingly valuable for managing rolling reviews and complex data requirements associated with Fast Track programs.
- Siemens’ acquisition of Dotmatics: Siemens expanded its digital and scientific software capabilities through a $5 billion acquisition of Dotmatics. The deal strengthens support for biopharma companies seeking to combine AI-powered drug discovery with accelerated regulatory development strategies.
Expanding Global Regulatory Alignment
Expedited regulatory pathways are increasingly influencing deal activity beyond the United States, supported by parallel reforms in international markets. Streamlined approval frameworks—particularly in China—are driving cross-border licensing and strategic partnerships, aided by evolving regulations such as the revised Drug Administration Law of the People’s Republic of China.
To monitor these developments and assess emerging investment opportunities, industry stakeholders are leveraging intelligence platforms such as IQVIA and the Evaluate forecasting hub to track regulatory milestones and market activity.
Examples:
- AstraZeneca’s partnership with CSPC Pharmaceutical Group: AstraZeneca entered an $18.5 billion licensing partnership with China-based CSPC Pharmaceutical Group, gaining access to rapid multi-regional clinical trial enrollment capabilities and faster NMPA review timelines to support global regulatory submissions.
- GSK’s collaboration with Hengrui Pharmaceuticals: GlaxoSmithKline (GSK) signed an out-licensing and co-development agreement valued at more than $12 billion with Jiangsu Hengrui Pharmaceuticals. The partnership focuses on advanced oncology therapies, including antibody-drug conjugates, designed to pursue accelerated approval pathways across both Western and Asia-Pacific markets.